We recently demonstrated that blood-brain barrier permeabilization using mannitol enhances the therapeutic efficacy of systemically administered human umbilical cord blood (HUCB) 
Introduction
Cell therapy remains a controversial approach for treating human disorders [1] [2] [3] . Laboratory and clinical data are divided on transdifferentiation of cells from non-neuronal origin, with studies reporting failure of hematopoietic bone marrow cells to differentiate into brain cells [4, 5] , whereas equally compelling evidence demonstrates that peripherally transplanted adult human bone marrow cells in patients with hematologic malignancies entered the brain and generated neurons [6, 7] . Clinical trials of cell therapy for neurological disorders have been performed in Parkinson's disease, Huntington's disease and stroke [8] [9] [10] . Two [13] . The aim of the present study was drawn from our previous report [13] 
Statistical analysis
Behavioural scores and trophic factor expression levels were initially analyzed using ANOVA, followed by post hoc Bonferroni t-tests for pair-wise comparisons between treatment groups. The level of significance was set at Ͻ0.05. 
Results

Mannitol enhances behavioural recovery of HI-injured animals transplanted with HUCB
Mannitol up-regulates CNS growth factors in HI-injured animals transplanted with HUCB
Parallel groups of animals from the three treatment conditions (n ϭ 5 per treatment group) were euthanized at day 3 posttransplantation for ELISA (Fig. 4) 
Fig. 2 Sporadic HUCB grafts survive in HI brains. Representative images of microscopically detected HUCB cells alone (A-D) and HUCB cells ϩ mannitol (E-H; adjacent section with high magnification images shown in I-K). Very few HuNu-positive HUCB cells (green) were detected in the HI-injured hippocampal dentate gyrus, which co-labelled with the nuclei marker Hoechst (blue). These data indicate that only a handful of intravenously transplanted HUCB cells reached the ischaemic hippocampus. Bar ϭ 60 m. Individual and mean cell counts of HuNu positive cells are shown in panels L and M, respectively.
Discussion
The [17, 18] and others caused by brain infections [19] , such as bacterial meningitis or viral encephalitis, or head injury from perinatal brain damage [20] , vehicular accident [21] or child abuse and neglect [22] . There is no cure for cerebral palsy, but physical therapy [23] The present HUCB cell dose of 15k is dramatically low compared with previously reported therapeutically active doses for HUCB. In our previous study in adult stroke [13] , we found that 200,000 HUCB cells (already considered a low dose) when combined with mannitol mimics those seen in other reports using much higher doses (Ͼ500,000 cells without mannitol) of IV HUCB in stroke [28, 29] [32] . We have previously shown that cultured [33, 34] [13, 27, 37, 38] . This concept of 'bystander effects' (i.e. growth factor secretion) overriding the 'cell replacement' (i.e. graft survival) has recently received direct scientific support [39, 40] . Of note, we observed here that HUCB grafts alone or in combination with mannitol partially normalized dendritic density in hippocampal CA1 region, suggesting neurotrophic factor effects.
E. of control (A). (B) Vehicle, (C) Mannitol, (D) HUCB alone and (E) HUCB ϩ mannitol. Quantitative analyses are shown in (F
These results, taken together, advance the strategy of BBB permeation via mannitol treatment as an adjunct to intravenous transplantation of HUCB for treating neonatal HI injury, as demonstrated previously in adult stroke [13] . The present therapeutic benefits of combined mannitol and HUCB were achieved without immunosuppression, which is often accompanied by deleterious side effects, thereby further paving the way for autologous, as well as allograft transplantation.
